Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7442 (Evusheld) PK/Safety in Pediatric Participants for COVID-19
NCT05281601Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Primary endpoints: Serum Concentrations of AZD7442 at Day 366, Maximum Serum Concentration and 5 more. Started Mar 2022; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05281601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281601.